|Systematic (IUPAC) name|
|Mol. mass||398.37 g/mol|
|14px (what is this?)|
Lu AE58054 is a potent and selective 5-HT6 receptor antagonist under development by Lundbeck as an augmentation therapy for the treatment of cognitive deficits associated with Alzheimer's disease and schizophrenia. As of October 2013 it is in phase III clinical trials.
- Lundbeck expands its pipeline - initiating phase II clinical trials with a new compound for the treatment of schizophrenia
- Lundbeck initiates clinical phase II trials with Lu AE58054 as augmentation treatment in Alzheimer's disease